Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
CNTX
Strong SellSinkerContext Therapeutics Inc. · Healthcare · United States · $56M · Avg Vol: $719K/d
COMPANY DESCRIPTION
Context Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel treatments for various cancers, with a particular focus on women's oncology. Its competitive position relies on the successful progression of its pipeline candidates, including its lead asset, onapristone extended-release, through clinical trials to address unmet medical needs.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | — | — | — |
| EPS | -0.16 | -0.26 | -0.46 | -0.38 | — | -0.48 | -0.46 | -0.44 | — |
| Shares | 91.9M | 91.9M | 89.7M | 91.9M | 0.0% | 91.9M | — | — | — |
| Debt | 55.1K | 0 | 0.2M | 0.1M | 26.7% | 0.2M | — | — | — |
| Equity | 34.8M | 11.9M | 95.3M | 60.5M | 20.3% | — | — | — | — |
| Op CF | -13.5M | -21.0M | -14.6M | -26.4M | — | -34.0M | — | — | — |
| Inv CF | -0.5M | 0 | -14.8M | -2.0M | — | — | — | — | — |
| Fin CF | -0.1M | 0 | 109.3M | -15.3K | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CNTX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| CNTX | Context Therapeutics Inc.(you) | $56M | 6 | Strong Sell |
| ATYR | aTyr Pharma, Inc. | $53M | 7 | Strong Sell |
| HRTX | Heron Therapeutics, Inc. | $62M | 7 | Strong Sell |
| KALA | KALA BIO, Inc. | $63M | 7 | Strong Sell |
| TCRX | TScan Therapeutics, Inc. | $51M | 7 | Strong Sell |
| FLNA | Filana Therapeutics, Inc. | $58M | 4 | Strong Sell |
| MCRB | Seres Therapeutics, Inc. | $51M | 8 | Strong Sell |
| TIL | Instil Bio, Inc. | $51M | 9 | Strong Sell |
| CRDF | Cardiff Oncology, Inc. | $73M | 7 | Strong Sell |
| CING | Cingulate Inc. | $77M | 6 | Strong Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.3%